Announcements Trials
Browse Landscape

Phase

Phase NA 3Phase 2 3Phase 4 1Phase 1/2 1Phase 1 1

Status

Terminated 3Completed 2Withdrawn 1Unknown 1Recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 2

Conditions

Breast Neoplasms 413Carcinoma, Non-Small-Cell Lung 286Prostatic Neoplasms 208Neoplasms 204Neoplasm Metastasis 180Melanoma 164Multiple Myeloma 158Colorectal Neoplasms 158Leukemia, Myeloid, Acute 143Lung Neoplasms 132Leukemia 126Lymphoma 118Pancreatic Neoplasms 117Recurrence 111Ovarian Neoplasms 111Leukemia, Lymphocytic, Chronic, B-Cell 110Lymphoma, Non-Hodgkin 105Carcinoma, Renal Cell 104Brain Neoplasms 90Myelodysplastic Syndromes 88Precursor Cell Lymphoblastic Leukemia-Lymphoma 86Glioblastoma 85Lymphoma, Large B-Cell, Diffuse 80Lymphoma, Follicular 79Carcinoma, Hepatocellular 79Head and Neck Neoplasms 77Squamous Cell Carcinoma of Head and Neck 76Urinary Bladder Neoplasms 66Stomach Neoplasms 61Hodgkin Disease 60

Interventions

secukinumab 1Vitamin E 1MEDI2070 1Iron-Dextran Complex 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Terminated × Crohn Disease × Clear all
NCT02574637 2021-05-26

Evaluation of Efficacy and Safety of Brazikumab (MEDI2070) in Participants With Active, Moderate to Severe Crohn's Disease

AstraZeneca

Phase 2 Terminated
29 enrolled 25 charts

Crohn Disease, Inflammatory Bowel Diseases

NCT00584740 2015-03-31

Efficacy, Safety and Tolerability of AIN457 in Moderate to Severe Active Crohn's Disease

Novartis

Phase 2 Terminated
59 enrolled 13 charts
Lymphoid

Crohn Disease, Lymphoma, Follicular, Motor Activity

NCT00152841 2009-03-17

Effect of Iron and Vitamin E Supplementation on Disease Activity in Patients With Either Crohn's Disease or Ulcerative Colitis

University Health Network, Toronto

Phase 2 Terminated
30 enrolled
Lymphoid

Colitis, Ulcerative, Crohn Disease, Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡